Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-K. pneumoniae in Febrile Neutropenic Patients with Acute Leukemia Who are Colonized with KPC-K. pneumoniae. A 7-Years Retrospective Observational Cohort Study

References

• Tofas P, Skiada A, Angelopoulou M, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases. Int J Antimicrob Agents. 2016;47:335–339. doi:10.1016/j.ijantimicag.2016.01.011
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Pagano L, Martino B, et al. Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. Am J Hematol. 2016;91(11):1076–1081. doi:10.1002/ajh.24489
   PubMed Web of Science ®Google Scholar
• Poucha SM, Satlin MJ. Carbapenem-resistant Enterobacteriaceae in special populations: solid organ transplant recipients, stem cell transplant recipients, and patients with haematologic malignancies. Virulence. 2017;8:391–402. doi:10.1080/21505594.2016.1213472
   PubMed Web of Science ®Google Scholar
• Micozzi A, Gentile G, Minotti C, et al. Carbapenem-resistant Klebsiella pneumoniae in high-risk haematological patients: factors favouring spread, risk factors and outcome of carbapenem-resistant Klebsiella pneumoniae bacteraemias. BMC Infect Dis. 2017;17:203. doi:10.1186/s12879-017-2297-9
   PubMed Web of Science ®Google Scholar
• Micozzi A, Gentile G, Santilli S, et al. Reduced mortality from KPC-K. pneumoniae bloodstream infection in high-risk patients with haematological malignancies colonized by KPC-K. pneumoniae. BMC Infect Dis. 2021;21:1079. doi:10.1186/s12879-021-06747-8
   PubMed Web of Science ®Google Scholar
• Martinez-Nadal G, Puerta-Alcalde P, Gudiol C, et al. Inappropriate empiric antibiotic treatment in high-risk neutropenic patients with bacteraemia in the era of multidrug resistance. Clin Infect Dis. 2020;70:1068–1074. doi:10.1093/cid/ciz319
   PubMed Web of Science ®Google Scholar
• Amit S, Mishali H, Kotlovsky T, Schwaber MJ, Carmeli Y. Bloodstream infections among carriers of carbapenem-resistant Klebsiella pneumoniae: etiology, incidence and predictors. Clin Microbiol Infect. 2015;21:30–34. doi:10.1016/j.cmi.2014.08.001
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Di Blasi R, Skert C, et al. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97:1717–1726. doi:10.1007/s00277-018-3341-6
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56–e93. doi:10.1093/cid/cir073
   PubMed Web of Science ®Google Scholar
• Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European conference on infections in leukaemia. Haematologica. 2013;98:1826–1835. doi:10.3324/haematol.2013.091025
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Picardi M, et al. Results of a multicentre, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia. J Clin Oncol. 2014;32:1463–1471. doi:10.1200/JCO.2013.51.6963
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Averbuch D, Castagnola E, et al. 8th European conference on infections in leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22(6):e270–e280. doi:10.1016/S1470-2045(20)30725-7
   PubMed Web of Science ®Google Scholar
• Micozzi A, Assanto GM, Cesini L, et al. Reduced transmission of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) in patients with haematological malignancies hospitalized in an Italian hospital during the COVID-19 pandemic. JAC Antimicrob Resist. 2021;3:dlab167. doi:10.1093/jacamr/dlab167
   PubMedGoogle Scholar
• Micozzi A, Ansuinelli M, Minotti C, et al. Ceftazidime-avibactam as empirical therapy in febrile neutropenic high-risk haematological patients colonized with carbapenem-resistant Klebsiella pneumonia. 28th ECCMID, the European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 21–24 April 2018. Paper Poster Session P0681; 2018.
   Google Scholar
• Forcina A, Baldan R, Marasco V, et al. Control of infectious mortality due to carbapenemase-producing Klebsiella pneumoniae in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(1):114–119. doi:10.1038/bmt.2016.234
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58(4):2322–2328. doi:10.1128/AAC.02166-13
   PubMed Web of Science ®Google Scholar
• Perez F, Chakhtoura NG, Papp-Wallace KM, Wilson BM, Bonomo RA. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17(6):761–781. doi:10.1517/14656566.2016.1145658
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2018;24(2):133–144. doi:10.1016/j.cmi.2017.08.030
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734. doi:10.1016/S1473-3099(17)30228-1
   PubMed Web of Science ®Google Scholar
• Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018;4:e00079. doi:10.1128/CMR.00079-17
   Google Scholar
• King M, Heil E, Kuriakos S, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2017;61(7):e00449–e00517. doi:10.1128/AAC.00449-17
   PubMed Web of Science ®Google Scholar
• Shields RK, Hong Nguyen M, Chen L, Press EG, Potoski BA, Marini RV. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother. 2017;61(8):e00883–e00917. doi:10.1128/AAC.00883-17
   PubMed Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clin Infect Dis. 2018;66(2):163–171. doi:10.1093/cid/cix783
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for KPC-Klebsiella pneumoniae infections: a retrospective observational multicentre study. Clin Infect Dis. 2021;73:1664–1676. doi:10.1093/cid/ciab176
   PubMed Web of Science ®Google Scholar
• Castón JJ, Lacort-Peralta I, Martín-Dávila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteraemia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118–123. doi:10.1016/j.ijid.2017.03.021
   PubMed Web of Science ®Google Scholar
• Criscuolo M, Trecarichi EM. Ceftazidime/Avibactam and ceftolozane/Tazobactam for multidrug-resistant gram negatives in patients with haematological malignancies: current experiences. Antibiotics. 2020;9:58. doi:10.3390/antibiotics9020058
   Google Scholar
• Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs. 2018;78:65–98. doi:10.1007/s40265-017-0851-9
   PubMed Web of Science ®Google Scholar
• Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P. Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther. 2021;10:1989–2034. doi:10.1007/s40121-021-00507-6
   PubMed Web of Science ®Google Scholar
• Li D, Fei F, Yu H, et al. Ceftazidime-avibactam therapy versus ceftazidime-avibactam-based combination therapy in patients with carbapenem-resistant gram-negative pathogens: a meta-analysis. Front Pharmacol. 2021;12:707499. doi:10.3389/fphar.2021.707499
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. (EUCAST, Version 10.0, 2020-01-01). Available from: http://www.eucast.org/clinical_breakpoints/. Accessed January 24, 2023.
   Google Scholar